Oxford Science Enterprises – For all our tomorrows

We build world-changing businesses.

Scientific breakthroughs can solve our biggest challenges – from infectious diseases and cancer to cyber security, shortages of natural resources, and rapid climate change. But only when they make it out of the lab.

We are Oxford Science Enterprises, the Science Business Builder. We want to help solve the world’s toughest problems for more people, in more places, faster. We particularly focus on four key goals:

Enabling people to lead longer, healthier lives

Protecting the future of our planet

Feeding the world and keeping us safe

Accelerating the pace of positive change

We do this by transforming world-leading science into world-changing businesses.

Updates

Retweet on Twitter Oxford Science Enterprises Retweeted

Alethiomics @alethiomics·

We are proud to be an @UniofOxford spin-out. The troubling stat in this report is the tiny proportion of women represented as a founder (14%) or director (8%) of spin-outs. Not us though! @beth_psaila is our co-founder and also sits on our board. https://tinyurl.com/alethiomicsox

Reply on Twitter 1526838645436477443 Retweet on Twitter 15268386454364774431 Like on Twitter 152683864543647744321 Twitter 1526838645436477443

Retweet on Twitter Oxford Science Enterprises Retweeted

University of Oxford@UniofOxford·

16 May

Oxford contributed £15.7 billion to the UK economy in one year.

For every £1 invested in the University’s research and knowledge exchange activities, £10.3 is generated for the UK economy.

Find out more about Oxford's impact ⬇️

Reply on Twitter 1526110704079474688 Retweet on Twitter 152611070407947468863 Like on Twitter 1526110704079474688224 Twitter 1526110704079474688

Oxford Science Enterprises @OxSciences·

12 May

The 2021 #REFResults have been published and show once again that the @UniofOxford is home to the largest volume of world-leading research in the UK. 👏

Find out more about the results here ⬇️:

https://bit.ly/3N6vVeb

#oxford #science #worldleadingresearch

Reply on Twitter 1524751586173472769 Retweet on Twitter 1524751586173472769 Like on Twitter 1524751586173472769 Twitter 1524751586173472769

Oxford’s REF 2021 results show largest volume of world-leading research

Salience Labs Raises $11.5 Million Seed to Develop Ultra High-speed Chips Using Photonics for AI Applications

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer

Oxford Science Enterprises Appoints Richard Laxer, Former Chairman and CEO of GE Capital, as a Non-Executive Director

Util announces the closing of a seed round

Refeyn closes Series B funding round

OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)

Vaccitech Announces Notification of Milestone and Royalty Revenue relating to sales of Vaxzevria®

Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

We build world-changing businesses.